Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors
Renguo Guan(Sun Yat-sen University), Rongping Guo(Sun Yat-sen University), Chong Zhong(Guangzhou University of Chinese Medicine), Zehao Zheng(Sun Yat-sen University), Guanjie Huang, Haitao Zhao(Huaiyin Normal University), Wei Wei(Zhujiang Hospital), Nan Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ye Lin(Sir Run Run Shaw Hospital), Min Deng(First Affiliated Hospital of Bengbu Medical College), Jie Mei(Sun Yat-sen University), Yizhen Fu(Sun Yat-sen University)
Cited by 36
Related Papers
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Evaluation of cell-free DNA approaches for multi-cancer early detection
|Cancer Cell|2022|311
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
|Signal Transduction and Targeted Therapy|2023|289
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216